SEPIA is online 🎉
We are pleased to publish our SEPIA platform 🥳 You can access SEPIA via this link trr241.hosting.rrze.uni-erlangen.de/SEPIA/#!/
We are pleased to publish our SEPIA platform 🥳 You can access SEPIA via this link trr241.hosting.rrze.uni-erlangen.de/SEPIA/#!/
June 18, 2025 at 7:43 AM
SEPIA is online 🎉
We are pleased to publish our SEPIA platform 🥳 You can access SEPIA via this link trr241.hosting.rrze.uni-erlangen.de/SEPIA/#!/
We are pleased to publish our SEPIA platform 🥳 You can access SEPIA via this link trr241.hosting.rrze.uni-erlangen.de/SEPIA/#!/
Two amazing days at the TRR241 Symposium in Berlin just wrapped up! Great talks, inspiring discussions, and lots of fresh ideas – big thanks to everyone who joined and made it such a special event. A special thank you to our sponsors for their generous support!
#TRR241 #Symposium #Berlin #IBD
#TRR241 #Symposium #Berlin #IBD
June 4, 2025 at 6:57 AM
Two amazing days at the TRR241 Symposium in Berlin just wrapped up! Great talks, inspiring discussions, and lots of fresh ideas – big thanks to everyone who joined and made it such a special event. A special thank you to our sponsors for their generous support!
#TRR241 #Symposium #Berlin #IBD
#TRR241 #Symposium #Berlin #IBD
Crohn’s disease and ulcerative colitis are the main types of IBD, with no cure. Rising incidence demands new therapies. TRR241 explores immune-epithelial crosstalk in IBD pathogenesis, uniting experts in Germany and Austria. Our research spans barrier regulation, immune response therapy development.
March 6, 2025 at 8:08 AM
Crohn’s disease and ulcerative colitis are the main types of IBD, with no cure. Rising incidence demands new therapies. TRR241 explores immune-epithelial crosstalk in IBD pathogenesis, uniting experts in Germany and Austria. Our research spans barrier regulation, immune response therapy development.